Myeloma Proteins as Tumor-Specific Transplantation Antigens

Abstract

MATERIALS AND METHODSImmunogens and Immunization Schedules. 10-to 12-week old female BALB/cAnN mice were injected with purified myelomaproteins 315 or 460, which were isolated by subjection of the proteins to mild reduction and alkylation (in this work with iodoacetic acid) (2, 3). Proteins 315 and 460 purified in this manner (820w,, = 6.5) have about eight carboxymethyl groups per molecule (150,000 daltons), one on the C-terminal or penultimate cysteine of the light chain and 3-4 on the heavy chain (4). Both purified proteins had intact ligandbinding sites, as shown by specific quenching of their tryptoAbbreviation: TD5o, number of cells required to produce tumors in 50% of control (untreated) animals; Dnp, 2,4-dinitrophenyl.

Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes

“…The tumour used in this study presents tumour-specific and tumour-associated antigens (Lynch et al, 1972;Comoglio and Forni, 1973) which can be employed to induce resistance in syngeneic animals. Previous work also indicated that the take and growth of this tumour is influenced LU e by spontaneous or artificially induced changes in host immune reactivity .…”

Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma

“…The first generation of Id vaccines consisted of purified Id or Id protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), 3 injected together with an immunologic adjuvant. Vaccination with these vaccines conferred protection against tumor challenge in a number of lymphoma and myeloma animal models (1)(2)(3)(4). Based on these preclinical results, immunization with autologous Id has been initiated in clinical trials to control residual disease in B cell lymphoma and multiple myeloma (5)(6)(7).…”

Variations in “rescuability” of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development

“…However, for this critical step to be reached, it was first necessary to demonstrate that idiotypic determinants present in the immunoglobulin borne by FL cells can serve both as a tumor-and patient-specific antigen ( Fig. 1; [3,4]). Subsequently, it was shown that immunization of FL patients against such a self-antigen was possible [5] and induced an idiotype-specific, humoral [5][6][7][8] and cellular [6,7,9] immune response.…”